Technical Analysis for APLT - Applied Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Bullish Engulfing | Bullish | -5.17% | |
| Crossed Above 20 DMA | Bullish | -5.17% | |
| Pocket Pivot | Bullish Swing Setup | -5.17% |
| Alert | Time |
|---|---|
| Down 5% | about 17 hours ago |
| Fell Below 20 DMA | about 21 hours ago |
| 20 DMA Support | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Down 2 % | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Myopathy Retinopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Myopathy Retinopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.39 |
| 52 Week Low | 1.18 |
| Average Volume | 947,176 |
| 200-Day Moving Average | 3.34 |
| 50-Day Moving Average | 5.46 |
| 20-Day Moving Average | 4.50 |
| 10-Day Moving Average | 4.61 |
| Average True Range | 0.36 |
| RSI (14) | 39.02 |
| ADX | 16.78 |
| +DI | 22.29 |
| -DI | 20.06 |
| Chandelier Exit (Long, 3 ATRs) | 4.22 |
| Chandelier Exit (Short, 3 ATRs) | 5.23 |
| Upper Bollinger Bands | 4.86 |
| Lower Bollinger Band | 4.14 |
| Percent B (%b) | 0.36 |
| BandWidth | 16.02 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.25 |
| MACD Histogram | 0.0417 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.59 | ||||
| Resistance 3 (R3) | 5.71 | 5.45 | 5.39 | ||
| Resistance 2 (R2) | 5.45 | 5.14 | 5.38 | 5.32 | |
| Resistance 1 (R1) | 4.92 | 4.96 | 4.79 | 4.80 | 5.26 |
| Pivot Point | 4.66 | 4.66 | 4.59 | 4.59 | 4.66 |
| Support 1 (S1) | 4.13 | 4.35 | 4.00 | 4.01 | 3.54 |
| Support 2 (S2) | 3.87 | 4.17 | 3.80 | 3.48 | |
| Support 3 (S3) | 3.34 | 3.87 | 3.41 | ||
| Support 4 (S4) | 3.22 |
